Last reviewed · How we verify
Avastin
At a glance
| Generic name | Avastin |
|---|---|
| Also known as | Bevacizumab, bevacizumab, Avastin (bevacizumab), Avastin: bevacizumab., Avastin™ |
| Sponsor | Washington University School of Medicine |
| Target | Vascular endothelial growth factor A |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
- Carcinoma of cervix
- Glioblastoma multiforme
- Liver cell carcinoma
- Malignant epithelial tumor of ovary
- Malignant neoplasm of breast
- Malignant neoplasm of colon and/or rectum
- Malignant tumor of fallopian tube
- Malignant tumor of peritoneum
- Metastatic carcinoma to colon
- Metastatic renal cell carcinoma
- Non-small cell lung cancer with mutation in epidermal growth factor receptor
- Nonsquamous nonsmall cell neoplasm of lung
- Secondary malignant neoplasm of colon
Common side effects
- Epistaxis
- Headache
- Hypertension
- Rhinitis
- Proteinuria
- Taste alteration
- Dry skin
- Hemorrhage
- Lacrimation disorder
- Back pain
- Exfoliative dermatitis
- Fatigue
Serious adverse events
- Hemorrhage
- Thromboembolic events
- Disease progression
- Unacceptable toxicity
Key clinical trials
- Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer (PHASE3)
- Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (PHASE2, PHASE3)
- A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver) (PHASE1, PHASE2)
- A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies (PHASE2)
- A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer (PHASE2)
- Sintilimab Combined With Bevacizumab Biosimilar as Adjuvant Treatment After Resection of Ruptured Hepatocellular Carcinoma (CLEAR-2) (PHASE2)
- Bevacizumab In Hereditary Hemorrhagic Telangiectasia (PHASE2)
- A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Avastin CI brief — competitive landscape report
- Avastin updates RSS · CI watch RSS
- Washington University School of Medicine portfolio CI